公开(公告)号：US20240350527A1

公开(公告)日：2024-10-24

申请号：US18685067

申请日：2022-08-22

Applicant: AIM ImmunoTech Inc.

Inventor： Thomas K. EQUELS ,  David R. STRAYER

IPC: A61K31/713 ,  A61P43/00 ,  C12N15/117

CPC classification number: A61K31/713 ,  A61P43/00 ,  C12N15/117

Abstract: Disclosed is a method for treating a subject that has previously been infected with SARS-COV-2 and exhibiting at least one Post COVID-19 Conditions of fatigue (PCC of fatigue) symptom. The method comprises administering to the subject a therapeutically effective amount of a composition comprising therapeutic double-stranded RNA (tdsRNA). Compositions, medicaments and delivery systems comprising tdsRNA for the treatment of PCC of fatigue are also disclosed.

公开(公告)号：US20240316107A1

公开(公告)日：2024-09-26

申请号：US18740688

申请日：2024-06-12

Applicant: The Trustees of the University of Pennsylvania

Inventor： Yangbing Zhao ,  Jiangtao Ren

IPC: A61K35/17 ,  A61K39/00 ,  A61P35/00 ,  A61P37/02 ,  C12N9/22 ,  C12N15/10 ,  C12N15/117 ,  C12N15/90

CPC classification number: A61K35/17 ,  C12N9/22 ,  C12N15/102 ,  C12N15/117 ,  C12N15/90 ,  A61K2039/5158 ,  A61P35/00 ,  A61P37/02 ,  C12N2310/122 ,  C12N2310/20 ,  C12N2310/315

Abstract: The present invention includes compositions and methods for modifying primary T cells. In one aspect, the invention comprises administering to a cell a stem-loop Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) RNA (st-crRNA) and a Cpf1 enzyme.

公开(公告)号：US20240226335A9

公开(公告)日：2024-07-11

申请号：US18471738

申请日：2023-09-21

Applicant: The Trustees of the University of Pennsylvania

Inventor： Katalin Kariko ,  Drew Weissman

IPC: A61K48/00 ,  A61K38/17 ,  A61K38/18 ,  A61K38/50 ,  C07H21/02 ,  C07K14/47 ,  C07K14/505 ,  C12N5/071 ,  C12N5/074 ,  C12N15/117 ,  C12N15/67 ,  C12N15/85 ,  C12Q1/68

CPC classification number: A61K48/0066 ,  A61K38/177 ,  A61K38/1816 ,  A61K38/50 ,  A61K48/0041 ,  A61K48/005 ,  A61K48/0075 ,  C07H21/02 ,  C07K14/47 ,  C07K14/4712 ,  C07K14/505 ,  C12N5/0602 ,  C12N5/0696 ,  C12N15/117 ,  C12N15/67 ,  C12N15/85 ,  C12Q1/68 ,  C12Y305/04004 ,  A61K48/00 ,  C12N2310/17 ,  C12N2310/33 ,  C12N2310/3341 ,  C12N2501/40 ,  C12N2800/95

Abstract: This invention provides RNA, oligoribonucleotide, and polyribonucleotide molecules comprising pseudouridine or a modified nucleoside, gene therapy vectors comprising same, methods of synthesizing same, and methods for gene replacement, gene therapy, gene transcription silencing, and the delivery of therapeutic proteins to tissue in vivo, comprising the molecules. The present invention also provides methods of reducing the immunogenicity of RNA, oligoribonucleotide, and polyribonucleotide molecules.

公开(公告)号：US12023375B2

公开(公告)日：2024-07-02

申请号：US17713149

申请日：2022-04-04

Applicant: University of Washington through its Center for Commercialization

Inventor： Michael J. Gale, Jr. ,  Gretja Schnell ,  Yueh-Ming Loo

IPC: A61K39/12 ,  A61K31/00 ,  A61K39/39 ,  A61K45/06 ,  C07H21/04 ,  C12N15/117 ,  A61K39/00

CPC classification number: A61K39/12 ,  A61K31/00 ,  A61K39/39 ,  A61K45/06 ,  C07H21/04 ,  C12N15/117 ,  A61K2039/555 ,  A61K2039/55561 ,  A61K2039/57 ,  C12N2310/17 ,  C12N2770/24134 ,  C12N2770/24232 ,  C12N2770/24234 ,  C12N2770/24271 ,  Y02A50/30

Abstract: Compositions and methods are provided that enable activation of innate immune responses through RIG-I like receptor signaling. The compositions and methods incorporate synthetic nucleic acid pathogen associated molecular patterns (PAMPs) that comprise elements initially characterized in, and derived from, the hepatitis C virus genome.

公开(公告)号：US20240148902A1

公开(公告)日：2024-05-09

申请号：US18277944

申请日：2022-02-18

Applicant: ENGENE, INC. ,  Marie-Line GOULET ,  Jose LORA ,  Shauna DAUPHINEE

Inventor： Marie-Line GOULET ,  Jose LORA ,  Shauna DAUPHINEE

IPC: A61K48/00 ,  A61K9/00 ,  A61P35/00 ,  C07K14/54 ,  C12N15/117

CPC classification number: A61K48/005 ,  A61K9/0019 ,  A61K48/0041 ,  A61P35/00 ,  C07K14/5434 ,  C12N15/117 ,  C12N2310/17

Abstract: The present disclosure relates to methods and compositions for the localized expression of IL-12, preferably in combination with an RIG-I agonist, for activating a memory T cell response to a cancer antigen. In embodiments, the method is effective for treating metastatic disease.

公开(公告)号：US20240141383A1

公开(公告)日：2024-05-02

申请号：US18548676

申请日：2022-03-04

Applicant: Kriya Therapeutics, Inc.

Inventor： Nachi GUPTA ,  Michele STONE

IPC: C12N15/86 ,  A61P37/06 ,  C12N15/117

CPC classification number: C12N15/86 ,  A61P37/06 ,  C12N15/117 ,  C12N2310/17 ,  C12N2750/14143 ,  C12N2750/14152

Abstract: The present disclosure provides the vector constructs comprising (a) a polynucleotide comprising a promoter operably linked to a nucleic acid of interest; (b) a first terminal repeat and a second terminal repeat; and (c) a backbone polynucleotide comprising a nucleic acid sequence that modulates a Toll-like receptor (TLR). Some aspects of the disclosure are related to methods for packaging the nucleic acid of interest and the nucleic acid sequence that modulates the TLR in an AAV particle, and some aspects are related to methods of modulating an immune response in a subject, comprising administering to said subject an effective amount of such AAV particles.

公开(公告)号：US11920136B2

公开(公告)日：2024-03-05

申请号：US17187579

申请日：2021-02-26

Applicant: Tallac Therapeutics, Inc.

Inventor： Jaume Pons ,  Hong I. Wan ,  Tracy Chia-Chien Kuo ,  Curt W. Bradshaw ,  Son Lam ,  Bang Janet Sim ,  Edward HyungSuk Ha ,  Sukumar Sakamuri

IPC: C12N15/117 ,  A61K47/68 ,  A61P35/00 ,  C07K16/28 ,  C07K16/30 ,  C07K16/32 ,  C07K19/00

CPC classification number: C12N15/117 ,  A61K47/6807 ,  A61K47/6811 ,  A61K47/6849 ,  A61K47/6851 ,  A61K47/6889 ,  A61P35/00 ,  C07K16/2803 ,  C07K16/30 ,  C07K16/32 ,  C07K19/00 ,  C07K2317/52 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/71 ,  C12N2310/17 ,  C12N2310/313 ,  C12N2310/315 ,  C12N2310/3513

Abstract: The present disclosure provides for antibody-oligonucleotide conjugates, methods of preparation thereof, and methods of use thereof. Also provided are related compounds, compositions and kits.

公开(公告)号：US11879126B2

公开(公告)日：2024-01-23

申请号：US18048390

申请日：2022-10-20

Applicant: Nutcracker Therapeutics, Inc.

Inventor： Samuel Deutsch ,  Daniel Frimannsson ,  Nicole Fay ,  Colin McKinlay ,  Ole Haabeth

IPC: C12N15/117 ,  A61P35/00 ,  A61K9/14 ,  A61K45/06 ,  C07K16/28

CPC classification number: C12N15/117 ,  A61K9/145 ,  A61K45/06 ,  A61P35/00 ,  C07K16/2818

Abstract: Provided herein are examples of mRNA treatment nanoparticles and methods of using them to treat a patient. An mRNA treatment nanoparticle may include one or more mRNAs encoding a tumor-specific antigen and an immunomodulatory agent; and a delivery vehicle molecule encapsulating the one or more mRNAs.

公开(公告)号：US20230383300A1

公开(公告)日：2023-11-30

申请号：US18176021

申请日：2023-02-28

Applicant: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY ,  EMORY UNIVERSITY

Inventor： Howard Y. Chang ,  Ye Grace Chen ,  Bali Pulendran ,  Sudhir Kasturi

IPC: C12N15/67 ,  A61K39/39 ,  C12N15/117

CPC classification number: C12N15/67 ,  A61K39/39 ,  C12N15/117 ,  A61K2039/55555

Abstract: Compositions and methods of modulating an innate immune response with circular RNAs are disclosed. In particular, the disclosure relates to methods for modifying an RNA by circularization and the use of circular RNAs generated with exogenous introns to stimulate an innate immune response or circular RNAs generated with endogenous introns to prevent immune recognition of foreign RNA.

公开(公告)号：US11814627B2

公开(公告)日：2023-11-14

申请号：US16311770

申请日：2017-06-15

Applicant: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY ,  EMORY UNIVERSITY

Inventor： Howard Y. Chang ,  Ye Grace Chen ,  Bali Pulendran ,  Sudhir Kasturi

IPC: A61K48/00 ,  C12N15/67 ,  A61K39/39 ,  C12N15/117 ,  A61K39/00

CPC classification number: C12N15/67 ,  A61K39/39 ,  C12N15/117 ,  A61K2039/55555 ,  C12N2310/17 ,  C12N2310/532

Abstract: Compositions and methods of modulating an innate immune response with circular RNAs are disclosed. In particular, the disclosure relates to methods for modifying an RNA by circularization and the use of circular RNAs generated with exogenous introns to stimulate an innate immune response or circular RNAs generated with endogenous introns to prevent immune recognition of foreign RNA.